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Introduction
The ataxia telangiectasia (A-T) mutated (ATM) kinase plays 
a key role in the DNA damage response by phosphorylating 
numerous  substrates  that  signal  for  DNA  repair,  cell  cycle 
checkpoint activation, and apoptosis (Banin et al., 1998; Canman 
et al., 1998; Matsuoka et al., 2007; Bensimon et al., 2010; Olsen 
et al., 2010; Beli et al., 2012). The critical function of ATM 
is underscored by its high conservation in eukaryotes and its 
deficiency in the recessive, cancer-prone A-T disease (Savitsky 
et al., 1995). The exact mechanism by which ATM is activated in 
vivo still remains unclear (Pellegrini et al., 2006; Daniel et al., 2008), 
but  one  current  model  suggests  that  autophosphorylation 
triggers its activation (Bakkenist and Kastan, 2003; Kozlov 
et al., 2006, 2011; So et al., 2009). A prediction is that loss 
of ATM kinase activity would be equivalent to loss of the ATM 
protein. Indeed, patient cells reconstituted with kinase-inactive 
ATM (Bakkenist and Kastan, 2003) and treatment of cells with 
a pharmacological ATM kinase inhibitor (Hickson et al., 2004; 
Bredemeyer et al., 2006; Callén et al., 2007; Rainey et al., 2008; 
White et al., 2008) support the notion that inhibition of cellular 
ATM kinase activity mirrors complete ATM deficiency.
The classical form of A-T is most frequently caused by 
compound heterozygote-truncating mutations that result in a total 
loss of destabilized ATM protein (90% of cases; Gilad et al., 
1996; Lakin et al., 1996; Li and Swift, 2000; Micol et al., 2011). 
A
taxia telangiectasia (A-T) mutated (ATM) is a 
key deoxyribonucleic acid (DNA) damage sig-
naling kinase that regulates DNA repair, cell 
cycle checkpoints, and apoptosis. The majority of patients 
with A-T, a cancer-prone neurodegenerative disease, 
present  with  null  mutations  in  Atm.  To  determine 
whether the functions of ATM are mediated solely by 
its  kinase  activity,  we  generated  two  mouse  models 
containing single, catalytically inactivating point muta-
tions in Atm. In this paper, we show that, in contrast to 
Atm-null mice, both D2899A and Q2740P mutations cause 
early embryonic lethality in mice, without displaying 
dominant-negative  interfering  activity.  Using  condi-
tional deletion, we find that the D2899A mutation in 
adult mice behaves largely similar to Atm-null cells but 
shows greater deficiency in homologous recombina-
tion  (HR)  as  measured  by  hypersensitivity  to  poly   
(adenosine diphosphate-ribose) polymerase inhibition 
and increased genomic instability. These results may 
explain why missense mutations with no detectable kinase 
activity are rarely found in patients with classical A-T. We 
propose  that  ATM  kinase-inactive  missense  mutations, 
unless  otherwise  compensated  for,  interfere  with  HR 
during embryogenesis.
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locus to generate BAC transgenic mice as previously described 
(Pellegrini et al., 2006; Daniel et al., 2008). Both mutation sites 
were confirmed by sequencing (Fig. 1 C). Founder lines ex-
pressing mutant murine ATM from the BAC transgene were 
identified and bred to Atm
+/. Founder lines G1 and H7 of   
Atm
TgD2899A mice expressed transgenic murine ATM near the 
level observed in Atm
+/ mice, whereas founder lines F5, D4, 
and I2 overexpressed murine ATM (Fig. 1 D). For Atm
TgQ2740P 
mice, founder line G4 expressed transgenic murine ATM near 
the  level  observed  in  Atm
+/+  mice,  whereas  the  C8  and  A3 
founder lines overexpressed ATM (Fig. 1 E). Similar ATM 
protein levels were observed from splenocytes and thymocytes of 
transgenic animals (Fig. 1, D and E; and not depicted).
We crossed Atm
TgD2899AAtm
+/ and Atm
TgQ2740PAtm
+/ mice 
with Atm
+/ but, to our surprise, failed to generate transgenic 
animals on the Atm
/ background (Fig. 1, F and G). This failure 
to generate Atm
TgAtm
/ live-born pups was observed across 
all founder lines of both mutations (Fig. 1, F and G) and was 
not the result of transgene integration on the chromosome con-
taining endogenous Atm, as shown by FISH (Fig. S1). To   
begin  to elucidate the stage of embryonic development that is   
impaired with deficient ATM kinase activity, we prepared 
embryos at embryonic day 9.5 (E9.5) from D2899A mutant 
mice. We found that Atm
TgD2899AAtm
/ embryos were produced at 
a  dramatically  lower  frequency  than  expected,  indicating  that 
D2899A mutant embryos die before E9.5 (Table 1). Transgenic 
animals with one or both WT copies of Atm were found at the   
expected frequency, indicating an absence of dominant-negative 
interfering  activity.  We  conclude  that  the  kinase-inactive 
ATM mutation leads to early embryonic lethality in mice.
We speculated that the severe defect during embryogenesis 
is the result of ATM kinase recruitment at DNA breaks, which 
may impair the function of other proteins by occluding their ac-
cess to DNA damage. To support this, we found that a kinase- 
inactive human ATM D2870A mutant protein, expressed in cells 
that do not express endogenous ATM, is recruited to sites of laser-
induced DNA damage (Fig. S2). Moreover, WT human ATM was 
similarly recruited to DNA damage sites in cells treated with the 
KU55933 ATMi (Fig. S2). These results are consistent with other 
studies in human cells showing that ATM kinase activity is dis-
pensable for recruitment of epitope-tagged ATM to sites of DNA 
breaks after laser- or ionizing radiation (IR)–induced DNA dam-
age (Barone et al., 2009; Davis et al., 2010). They are also consis-
tent with results from Xenopus laevis egg extracts showing an 
increase in ATM association to damaged chromatin in the pres-
ence of caffeine or the KU55933 ATMi (You et al., 2007, 2009).
Double-stranded  break  (DSB)–induced  activation  and 
recruitment of ATM to chromatin is dependent on Nbs1 (Uziel 
et al., 2003; Difilippantonio et al., 2005). If recruitment of   
kinase-dead ATM to DNA breaks is toxic, we reasoned that 
we might be able to rescue viability by breeding with Nbs1
B/B 
mice, a hypomorphic Nbs1 mutant mouse that exhibits a mild 
defect in ATM activation (Williams et al., 2002). However, no 
Nbs1
B/BAtm
TgD2899AAtm
/ mice were born (Table 2). Thus, a 
mutation that is predicted to reduce ATM activation and 
association with chromatin cannot rescue viability of ATM   
kinase-inactive mice.
Mouse models deficient in ATM have been invaluable for 
the study of A-T (Barlow et al., 1996; Elson et al., 1996; Xu et al., 
1996; Difilippantonio and Nussenzweig, 2007; Lavin, 2008; 
Stracker and Petrini, 2011). In stark contrast to Atm-null mice 
(Barlow et al., 1996; Elson et al., 1996; Xu et al., 1996), we 
show here that single point mutations disrupting the kinase 
activity of ATM lead to early embryonic lethality in mice. These 
results reveal a previously unknown essential role for ATM 
kinase activity during embryonic development and provide a 
potential explanation for why kinase-inactive missense muta-
tions do not constitute a significant portion of the molecular 
lesions in childhood A-T. Furthermore, our finding that inhibi-
tion of ATM kinase activity in vivo does not always equate   
to complete loss of ATM protein suggests that treatments   
using ATM  inhibitors  (ATMi’s)  could  be  more  toxic  than 
previously anticipated.
Results and discussion
Mutations in the ATM kinase domain 
display severely impaired kinase activity  
in vitro and cause embryonic lethality in mice
To determine whether the diverse in vivo functions of ATM 
are mediated solely by its kinase domain, we used bacterial 
artificial chromosome (BAC) recombineering to generate two 
kinase-inactive mouse models of ATM. To identify a single resi-
due for mutagenesis without any high-resolution structural in-
formation for ATM, we took two approaches. In a structural 
modeling approach, we identified the p110 phosphoinositide 
3-kinase domain as having a statistically significant protein 
sequence alignment with the ATM kinase domain and found that 
an essential catalytic aspartic acid residue in the active site of 
the  p110  kinase structure aligns with D2889 of human ATM. 
Moreover, a p110 knockin mouse substituting this residue with 
alanine,  p110
D910A/D910A,  demonstrated  that  this  mutation 
abolishes kinase activity in vitro and in vivo without affect-
ing protein stability (Okkenhaug et al., 2002); therefore, we chose 
to generate the conserved D2899A mutation in the mouse   
(Fig. 1 A). For the second approach, we decided to model   
a  rare  missense  variant  from  a  patient  with  classical A-T, 
c.8189A>C (p.Gln2730Pro), whose cells displayed ATM pro-
tein  expression  without  detectable  kinase  activity  (Taylor 
and Byrd, 2005; Barone et al., 2009).
Before generating BAC transgenic mouse models, we tested 
whether the D2889A and Q2730P mutations in human ATM are 
required for ATM kinase activity in a completely reconstituted 
system. Kinase assays with wild-type (WT), D2889A, and 
Q2730P mutant dimeric human ATM complexes were per-
formed using p53 as a substrate (Lee and Paull, 2005). Although 
WT ATM dimers displayed p53 S15 phosphorylation in an 
MRN (MRE11-RAD50-NBS1)- and DNA-dependent manner, 
kinase activity of D2889A and Q2730P mutant dimers was 
completely abolished (Fig. 1 B). Thus, the D2889A and Q2730P 
mutations are required for human ATM kinase activity.
As both D2889 and Q2730 residues in human ATM are 
conserved in the mouse (Fig. 1 A), we recombineered the equiv-
alent mutations in a WT BAC spanning the genomic mouse Atm 297 ATM kinase-dead mice are embryonically lethal • Daniel et al.
(Table 2), suggesting that disruption of DNA-PKcs recruitment 
to DNA breaks does not rescue ATM kinase-inactive toxicity. 
Similarly, loss of 53BP1, which reduces nonhomologous end 
joining (NHEJ) and promotes resection of DSBs (Ward et al., 
2004; Xie et al., 2007; Difilippantonio et al., 2008; Dimitrova   
et al., 2008; Bunting et al., 2010), also did not rescue the viability 
of Atm
TgD2899AAtm
/ mice (Table 2).
Conditional ATM D2899A B lymphocytes 
display defects in development, genome 
stability, and sensitivity to poly (ADP-
ribose) polymerase (PARP) inhibitor
To overcome the embryonic lethality of Atm
TgD2899AAtm
/ mice, 
we crossed a previously described conditional Atm knockout 
Recently, a DNA-dependent protein kinase, catalytic subunit 
(DNA-PKcs) mutant mouse model with three phosphorylation 
site  substitutions  revealed  that  the  DNA-PKcs  mutant  protein 
causes a more severe phenotype than Dnapkcs-null mice (Zhang 
et al., 2011). Because DNA-PKcs has overlapping functions 
with ATM (Gurley and Kemp, 2001; Sekiguchi et al., 2001; 
Callén et al., 2009; Gapud and Sleckman, 2011), we reasoned 
that if ATM and DNA-PKcs are being recruited to DNA breaks 
and occluding access of other factors, disruption of the DNA-
dependent protein kinase holoenzyme may partially alleviate 
the toxic effect of kinase-inactive ATM. To test this hypothesis, 
we crossed Ku80-null mice (Nussenzweig et al., 1996) with 
our  kinase-inactive  ATM  mice.  However,  Atm
TgD2899AAtm
/ 
live-born pups were not recovered in the Ku80
/ background 
Figure 1.  ATM D2899A and Q2740P mutations display severely impaired kinase activity in vitro and cause embryonic lethality in mice. (A) Pairwise   
local alignments of human (Homo sapiens) and mouse (Mus musculus) ATM protein sequences surrounding sites of mutagenesis. (B) Kinase assay with   
0.2 nM WT, D2889A, or Q2730P mutant dimeric human ATM, 3.6 nM MRN, 50 nM GST-p53 substrate, and linear DNA probed with an antibody to p53 
S15 phosphorylation. A titration of ATM is shown for each sample. (C) Sequence chromatograms showing the amino acid mutations generated in mouse 
BAC RP24-122F10. (D and E) Thymocytes were harvested for lysate preparation and Western blot analysis. Molecular mass markers are in kilodaltons. 
(F and G) Tables showing the expected and observed genotypes of 3-wk-old pups from breeding Atm
TgAtm
+/ with Atm
+/ mice. The boxes highlight the 
comparison between the total number of ATM kinase-inactive and Atm-null live-born pups.JCB • VOLUME 198 • NUMBER 3 • 2012   298
by Western blotting. Although Atm
flox/+ cells responded normally   
to    irradiation  with  robust  KAP1  S824  phosphorylation,   
Atm
TgD2899AAtm
flox/ and Atm
flox/ B cells behaved similarly, dis-
playing severely impaired phosphorylation (Fig. 2 A). We con-
clude that ATM D2899A mutant murine B cells are deficient 
in IR-induced ATM kinase activity in vivo similar to ATM-
deficient cells.
To assess the role of ATM kinase activity during B cell 
development, we performed flow cytometric analyses on freshly 
isolated  bone  marrow  and  splenocytes.  Atm
TgD2899AAtm
flox/ 
mice displayed significant decreases in the frequency and num-
ber of YFP
+ cells in developing and mature B cell subsets in 
bone marrow and spleen compared with the similar frequencies 
observed between Atm
flox/ and Atm
flox/+ mice (Fig. 2, B and C; 
and Fig. S3). Thus, different from ATM-deficient cells, Cre-
expressing YFP
+ cells with the D2899A mutant form of ATM as 
their sole ATM species are out competed in vivo by cells that ex-
press a WT copy of Atm. To test whether the D2899A mutation 
allele (Zha et al., 2008) and CD19-cre (Rickert et al., 1997) to 
our Atm transgenic mice for generating ATM kinase-inactive 
primary B cells. With this model, we investigated the effect 
of ATM kinase inhibition on DNA damage signaling, lymphocyte 
development, and genome stability. To monitor the frequency 
of Cre recombinase–expressing cells in these mice, we crossed 
in the Rosa26-stop-YFP allele (Srinivas et al., 2001) to generate 
Cd19
cre/+Rosa26
YFP/+Atm
TgD2899AAtm
flox/  mice  (herein  referred 
to as Atm
TgD2899AAtm
flox/) and compared with littermate ATM-
deficient control mice (Cd19
cre/+Rosa26
YFP/+Atm
flox/, herein 
referred to as Atm
flox/). To verify deletion efficiency, we sorted 
live YFP
+ cells from Atm
TgD2899AAtm
flox/ and control splenic 
B cell cultures and demonstrated that, although Atm
flox/ cells 
have no detectable ATM protein as measured by Western blotting, 
Atm
TgD2899AAtm
flox/  cells  displayed  levels  similar  to  Atm
flox/+ 
cells (Fig. 2 A). To test whether the D2899A mutation abrogates 
ATM kinase activity in vivo, splenic B cells were irradiated 
with 10 Gy, and KAP1 S824 phosphorylation was assessed 
Table 1.  Embryonic lethality of ATM D2899A mice occurs before E9.5
Founder line Atm
TgD2899AAtm
+/+ Atm
+/+ Atm
TgD2899AAtm
+/ Atm
+/ Atm
TgD2899AAtm
/ Atm
/ Total genotyped Absorb
G1 observed 3 9 7 13 1 5 38 5
G1 expected 5 5 10 10 5 5
H7 observed 0 5 2 8 0 2 17 2
H7 expected 2 2 4 4 2 2
D4 observed 0 4 0 1 0 0 5 1
D4 expected 0.5 0.5 1 1 0.5 0.5
F5 observed 1 4 5 2 0 0 12 3
F5 expected 1.5 1.5 3 3 1.5 1.5
I2 observed 4 3 4 6 0 2 19 4
I2 expected 2 2 5 5 2 2
Total E9.5 embryos  
observed
11 25 18 30 1 9 91 15
Total E9.5 embryos  
expected
11 11 23 23 11 11
Shown are the expected and observed genotypes from breeding Atm
TgD2899AAtm
+/ with Atm
+/ mice. Note the comparison between the total number of ATM kinase-
inactive and Atm-null embryos.
Table 2.  Embryonic lethality of ATM D2899A (G1 founder line) mice is not rescued by disruption of Nbs1, Ku80, or 53bp1
Genotype Atm
TgD2899AAtm
+/+ Atm
+/+ Atm
TgD2899AAtm
+/ Atm
+/ Atm
TgD2899AAtm
/ Atm
/
Nbs1
+/+ observed 9 10 14 10 0 11
Nbs1
+/+ expected 7 7 15 15 7 7
Nbs1
B/+ observed 16 20 42 38 0 16
Nbs1
B/+ expected 15 15 30 30 15 15
Nbs1
B/B observed 7 12 14 19 0 0
Nbs1
B/B expected 7 7 15 15 7 7
Ku80
+/+ observed 16 9 21 16 0 2
Ku80
+/+ expected 10 3 19 6 10 3
Ku80
+/ observed 21 16 41 26 0 9
Ku80
+/ expected 19 6 39 13 19 6
Ku80
/ observed 9 1 17 3 0 0
Ku80
/ expected 10 3 19 6 10 3
53bp1
/ observed 14 11 52 19 0 6
53bp1
/ expected 19 6 38 13 19 6
Shown are the expected and observed genotypes of 3-wk-old pups from breeding Nbs1
B/+Atm
TgD2899AAtm
+/ with Nbs1
B/+Atm
+/ mice (n = 238), intercrossing 
Ku80
+/Atm
TgD2899AAtm
+/ mice (n = 207), or intercrossing 53bp1
/Atm
TgD2899AAtm
+/ mice (n = 102). Note the numbers of ATM kinase-inactive live-born pups in 
the different Ku80 backgrounds, the comparison between the number of ATM kinase-inactive and Atm-null live-born pups in the 53bp1
-/- background, and the numbers 
of ATM kinase-inactive live-born pups in the different Nbs1 backgrounds.299 ATM kinase-dead mice are embryonically lethal • Daniel et al.
in B lymphocyte development and activation are only mildly 
more severe than ATM-deficient controls.
Chromosomal instability is a hallmark of both human and 
murine ATM-deficient cells (Xu et al., 1996; Shiloh, 2003; Callén 
et al., 2007) and is also a rapid consequence of treatment of 
WT cells with ATM kinase inhibitors (Hickson et al., 2004; 
Bredemeyer et al., 2006; Callén et al., 2007; Rainey et al., 2008; 
White  et  al.,  2008).  To  test  whether  genetic  ablation  of   
the  murine ATM  kinase  causes  defects  in  genome  stability, 
metaphase chromosome spreads of YFP
+ cells sorted from   
Atm
TgD2899AAtm
flox/ and control B cell cultures were analyzed 
for chromosome abnormalities. As expected, ATM-deficient cells 
causes defects in the overall fitness of stimulated cells, we 
activated  splenic  B  cells  in  culture  with  lipopolysaccharide 
(LPS) and IL4 and monitored YFP frequency of B220
+ cells 
over time by flow cytometry. Although YFP frequency in   
live Atm
flox/+ B cells remained constant over 6 d in culture,   
Atm
TgD2899AAtm
flox/ B cells displayed a reproducible decrease in 
YFP frequency, with Atm
flox/ B cells showing an intermedi-
ate phenotype (Fig. 2 D). Atm
TgD2899AAtm
flox/+ B cells expressing 
WT ATM showed similar results as Atm
flox/+ B cells (Fig. 2 D), 
supporting an absence of dominant-negative interfering activity 
in the D2899A mutant. Thus, although the D2899A point mutation 
in mice leads to severe defects in embryonic development, defects 
Figure 2.  Conditional ATM D2899A mice display defects mildly more severe than ATM deficiency in B cell development, genome stability, and sensitivity 
to PARP inhibitor. (A) Western blot analysis of splenic B cells stimulated with LPS and RP105 for 72 h, FACS sorted for YFP expression, and harvested for 
lysate preparation after a 10-Gy irradiation. Shown for comparison are sorted cells from two individual Atm
TgD2899AAtm
flox/ mice. In addition to the labeled 
Atm genotype, note that mice are also Cd19
cre/+Rosa26
YFP/+, for which YFP expression (as a marker of Cre recombinase expression) is found in pro-B cells 
and becomes progressively higher through B cell development to the mature B cell stage. Molecular mass markers are in kilodaltons. (B) YFP
+ frequency 
from freshly isolated B cells of the following subsets of bone marrow and spleen harvested and stained with antibodies to B220, CD43, and IgM for flow 
cytometric analysis. Pro-B (B220
+CD43
+IgM
), pre-B (B220
+CD43
IgM
), immature B (B220
+CD43
IgM
int), mature B (B220
+IgM
+), and splenic mature B 
(B220
+IgM
+) are shown. *, P < 0.00001. (C) YFP
+ absolute cell numbers from each subset in bone marrow and spleen. Legend same as in B. *, P < 0.05. 
(D) YFP
+ fraction of live B220
+ splenic B cells stimulated with LPS as a function of days in culture. Each data point represents the YFP
+ frequency measured 
by flow cytometry, relative to day 0. For days 5 and 6, P < 0.0001 for Atm
TgD2899AAtm
flox/ versus Atm
flox/+, and P < 0.05 for Atm
TgD2899AAtm
flox/ versus 
Atm
flox/. (E) Splenic YFP
+ B cells stimulated with LPS, IL4, and RP105 for 72 h were harvested for metaphase chromosome preparation. FISH was per-
formed on slides with a probe for telomeres and counterstained with DAPI. Frequency of aberrations per metaphase is shown for chromatid breaks (CTB), 
chromosome breaks (CSB), radials, and translocations (Atm
flox/+: n = 105 from 1 mouse; Atm
TgD2899AAtm
flox/: n = 313 from 3 mice; Atm
flox/: n = 200 from   
2 mice). (F) YFP
+ fraction of live B220
+ splenic B cells stimulated with LPS and 1 µM PARP inhibitor. Each data point represents the YFP
+ frequency measured 
by flow cytometry relative to no treatment of the same genotype. Legend same as in D. On days 3 and 4, P < 0.05 for Atm
TgD2899AAtm
flox/ versus Atm
flox/. 
Error bars represent standard deviation. PARPi, PARP inhibitor.JCB • VOLUME 198 • NUMBER 3 • 2012   300
splenic B cells from Atm
TgD2899AAtm
flox/ and control mice 
were stimulated with LPS and IL4, and the frequency of 
YFP
+ cells positive for surface IgG1 was assessed by flow 
cytometry. Consistent with previous studies using germ-
line Atm
/ mice (Lumsden et al., 2004; Reina-San-Martin et al., 
2004), B cells from Atm
flox/ mice with CD19-cre led to a 
2.5-fold decrease in IgG1 CSR, relative to the IgG1
+ fre-
quency in YFP
+ cells from Atm
flox/+ mice (Fig. 3, A and B). 
B  cells  from  Atm
TgD2899AAtm
flox/  mice  displayed  a  1.9-fold   
defect in IgG1 CSR, albeit less severe than ATM-deficient 
controls (Fig. 3, A and B). We conclude that ATM D2899A 
mutant B cells display defects in CSR that are mildly less   
severe than ATM-deficient controls.
DNA-PKcs and A-T and Rad3 related 
(ATR) are functional in conditional ATM 
D2899A B cells
Because DNA-PKcs and ATM have redundant roles in develop-
ment and CSR (Gurley and Kemp, 2001; Sekiguchi et al., 2001; 
Callén et al., 2009), we directly tested whether DNA-PKcs 
kinase activity is functional during CSR in D2899A mutant 
B cells. To this end, we stimulated Atm
TgD2899AAtm
flox/ and 
control cells to undergo CSR in the presence or absence of 
the DNA-PKcs inhibitor NU7026 (Callén et al., 2009). In contrast 
to Atm
flox/+ cells, inhibiting DNA-PKcs kinase activity in either 
Atm
TgD2899AAtm
flox/ or Atm
flox/ B cells resulted in a nearly twofold 
reduction in IgG1 CSR (Fig. 3 C), a decrease consistent with 
PKcs inhibitor treatment of germline Atm
/ B cells (Callén 
et al., 2009). We conclude that DNA-PKcs is functional in 
conditional ATM D2899A mutant B cells.
A different phosphoinositide 3-kinase–like kinase, ATR, 
is required for cell cycle progression and genome stability 
during replicative stress (Brown and Baltimore, 2003; López-
Contreras and Fernandez-Capetillo, 2010), and there is evidence 
that ATM can regulate ATR function. For example, ATM is 
required for ATR activation and CHK1 phosphorylation in 
response to IR; however, ATR-dependent CHK1 phosphoryla-
tion in response to replication-associated DNA damage occurs 
independently of ATM (Adams et al., 2006; Cuadrado et al., 
2006; Jazayeri et al., 2006; Myers and Cortez, 2006). To test 
whether ATR is functional in ATM D2899A mutant cells, we 
examined  CHK1  S317  phosphorylation  in  YFP
+  sorted   
Atm
TgD2899AAtm
flox/ and control cultured B cells treated with   
hydroxyurea. We found that hydroxyurea-induced CHK1 S317 
phosphorylation  was  indistinguishable  between  mutant  and 
control cells (Fig. 3 D). Double deficiency in the human ATM 
and ATR kinases leads to extensive chromosome fragmentation 
in the presence of the DNA replication inhibitor aphidicolin 
(Ozeri-Galai et al., 2008); however, Atm
TgD2899AAtm
flox/ cells 
were also indistinguishable from controls in response to aphidi-
colin in our previously described flow cytometric YFP fre-
quency assay (unpublished data). Altogether, our results indicate 
that expression of kinase-inactive murine ATM does not ab-
rogate DNA-PKcs or ATR function in B cells.
Although an explanation for the embryonic lethality in   
kinase-inactive ATM mice is yet to be determined, Atm-null muta-
tions clearly can become embryonically lethal when combined 
displayed a higher number of aberrations per cell compared 
with controls (Fig. 2 E). Atm
TgD2899AAtm
flox/ cells showed a 1.7-
fold increase in aberrations per cell compared with ATM-deficient 
cells, marked by chromosome breaks and chromatid breaks 
(Fig. 2 E). We conclude that ATM D2899A mutant murine   
B cells exhibit more genomic instability than ATM-deficient 
control cells.
The increase in chromatid breaks observed in D2899A 
mutant cells suggested that these cells may have more severely 
impaired homologous recombination (HR). To test this, we 
used flow cytometry to assess the YFP frequency of live B220
+ 
cells cultured with PARP inhibitor. Relative to the YFP fre-
quency measured with no drug treatment, this assay recapitu-
lated the reported sensitivity of ATM-deficient human cells to 
PARP inhibitor (Fig. 2 F; Bryant and Helleday, 2006; McCabe 
et al., 2006). Using YFP as a marker for Cre-expressing cells in 
competition with nondeleted cells, our analyses indicated that 
Atm
TgD2899AAtm
flox/ cells were mildly more sensitive to PARP 
inhibitor treatment compared with ATM-deficient cells (Fig. 2 F), 
suggesting a more significant defect in HR. We conclude that 
D2899A mutant murine B cells display more severe defects 
in genome stability and PARP inhibitor sensitivity compared 
with ATM-deficient cells.
Conditional ATM D2899A B lymphocytes 
display defects in variable, diversity, 
and joining (V(D)J) recombination and 
immunoglobulin class switching
Deficiency in murine ATM leads to impaired DNA end joining 
in lymphocytes undergoing V(D)J recombination (Bredemeyer 
et al., 2006). To test whether the D2899A mutation causes similar 
V(D)J recombination defects, we generated v-Abl (viral Abl) 
kinase-transformed pre-B cell lines (herein referred to as abl 
pre-B cells) from bone marrow of Atm
TgD2899AAtm
flox/ mice 
expressing  an  E-Bcl2  transgene. These  cells  were  transiently 
transfected with Cre recombinase to generate Atm
TgD2899AAtm
/ 
abl pre-B cells and retrovirally infected with the pMX-INV 
recombination substrate to generate Atm
TgD2899AAtm
/:INV 
abl pre-B cells. To induce recombination activating gene (RAG)–
mediated DSBs, Atm
+/+:INV, Atm
TgD2899AAtm
/:INV, and Atm
/: 
INV abl pre-B cells were treated with the Abl kinase inhibitor 
STI571. Southern blot analysis of pMX-INV rearrangement 
revealed  that  the  defects  in  V(D)J  recombination  in 
Atm
TgD2899AAtm
/:INV abl pre-B cells were similar to those 
observed in Atm
/:INV abl pre-B cells. Specifically, there 
was a decrease in normal coding joint formation with an accu-
mulation of unrepaired coding ends and an increase in hybrid 
joint formation (Fig. S3). We conclude that ATM D2899A 
mutant  murine  lymphocytes  display  V(D)J  recombination 
defects similar to Atm-null lymphocytes.
During an immune response, physiological DSBs at the 
IgH locus occur in B lymphocytes during class switch recom-
bination (CSR; Stavnezer et al., 2008). ATM is required for 
efficient CSR and has been proposed to play a role as a DNA 
damage response factor in the synapsis of two broken switch re-
gions (Pan et al., 2002; Lumsden et al., 2004; Reina-San-Martin 
et al., 2004). To test whether the D2899A mutation affects CSR, 301 ATM kinase-dead mice are embryonically lethal • Daniel et al.
In dividing embryonic cells, an HR defect in Nbs1
B/B mice 
may synergize with ATM deficiency to cause an accumulation 
of  DNA  damage  above  a  tolerable  threshold.  Similarly,  we 
found that D2899A mutant B cells were mildly more sensitive 
than ATM-deficient controls to PARP inhibition, and we hypothe-
size that this may be caused by a more severe decrease in resec-
tion. Although D2899A mutant B cells show a decrease in HR, 
they also  show  a  mild  increase  in  the  frequency  of  class 
switching compared with ATM-deficient cells, suggestive of 
increased NHEJ activity. Based on these findings, we sug-
gest that the mild imbalances in DNA repair pathways in   
Atm
TgD2899AAtm
/ cells above those governed by ATM could re-
sult in very severe developmental defects, while having less 
dramatic outcomes in adult tissues.
with deficiencies in various DNA damage response pathways. 
For instance, Atm-null mice show embryonic lethality when dis-
rupted in combination with Fancg
/ (Kennedy et al., 2007), 
Parp1
/ (E8.0; Ménisser-de Murcia et al., 2001), Parp2
/ 
(between E9.5 and newborn; Huber et al., 2004), Ku70
/ and 
Ku80
/ (earlier than E11.5), Dnapkcs
/ (E7.5–8.5; Gurley 
and Kemp, 2001; Sekiguchi et al., 2001; Gladdy et al., 2006), 
H2ax
/ (E11.5–12.5; Zha et al., 2008), and Nbs1
B/B (E10; 
Williams et al., 2002). Some of these synthetic lethal interactions 
may arise from additive defects in DNA repair. For example, 
it is possible that Nbs1
B/B mice are synthetically lethal with 
Atm
/ (Williams et al., 2002) because of the essential role 
of the MRN complex in DSB resection that is independent   
of its function in murine ATM activation (Buis et al., 2008). 
Figure 3.  Conditional ATM D2899A B cells display defects in immunoglobulin class switching without impairing DNA-PKcs or ATR. (A) Flow cytometric 
analysis of IgG1 expression on B cells stimulated with LPS and IL4 for 5 d. (B) Mean percentage of IgG1 class switching from multiple flow cytometric analy-
ses as in B (*, P < 0.05). (C) Mean percentage of IgG1 class switching of YFP
+ splenic B cells treated with DNA-PKcs inhibitor NU7026 (PKi) or DMSO   
(*, P < 0.05). (D) Splenic B cells stimulated with LPS and RP105 for 72 h were treated with 2 mM hydroxyurea (HU) for 2 h, FACS sorted for YFP expres-
sion, and harvested for lysate preparation and Western blot analysis. Shown for comparison are sorted cells from two individual Atm
TgD2899AAtm
flox/ mice 
along with Atm
+/+ and Atm
/ unsorted B cells. Molecular mass markers are in kilodaltons. Error bars represent standard deviation.JCB • VOLUME 198 • NUMBER 3 • 2012   302
on slides with a probe for telomere repeat–specific peptide nucleic acid con-
jugated to Cy3 fluorochrome (Panagene) and counterstained with DAPI. 
Metaphase images were acquired with an upright microscope (Axioplan 2; 
Carl Zeiss) equipped with a 63×, NA 1.4 objective lens (Plan-Apochromat; 
Nikon)  and  a  monochrome  charge-coupled  device  camera  (ORCA-ER; 
Hamamatsu Photonics) using MetaMorph software (Molecular Devices). Abl 
cell lines were generated, and V(D)J recombination was assayed as   
described  including  the  Atm
+/+:INV  (A70.3INV3)  and  Atm
/:INV   
(Atm
/INV14) lines (Bredemeyer et al., 2006). The pMX-INV retroviral re-
combination substrate contains GFP cDNA and human CD4 cDNA down-
stream of an internal ribosomal entry site. For Cre deletion in Atm
TgAtm
flox/ abl 
cells, cells were transfected with mouse stem cell virus–thy1.1-Cre plasmid 
DNA using the a transfection system (1,500 V/15 ms/4 pulses; Neon; Invitro-
gen). 24 h after transfection, cells were sorted using biotin anti-Thy1.1 anti-
bodies (BD) and antibiotin microbeads according to the company’s protocol 
(Miltenyi Biotec). The sorted cells were subcloned by limiting dilution and 
identified using a 3 ATM southern probe from a 635-bp fragment generated 
by PCR using 5-GGCATCTGCTTGACTGCAGTAAATCAGGCGG-3 and 
5-GGGGTACTGCAGCATAGGGCTGGAAGAGG-3 primers with stan-
dard procedures as described previously (Zha et al., 2008).
Western blotting
Whole-cell lysates from single-cell suspensions of thymocytes or B lympho-
cytes were prepared as previously described (Difilippantonio et al., 2005), 
and  Western  blotting  was  performed  as  previously  described  (Daniel   
et al., 2008). In brief, 40 µg protein was loaded on 4–12% Bis-Tris gels 
(NuPAGE; Life Technologies) and probed with the following antibodies us-
ing HRP-conjugated secondary antibodies and ECL Western blotting detec-
tion reagents (GE Healthcare): ATM (clone 5C2; 1:400; Novus Biologicals), 
-Tubulin (clone B512; 1:30,000; Sigma-Aldrich), KAP1 S824p (1:700; 
Bethyl Laboratories, Inc.), CHK1 S317p (1:500, Bethyl Laboratories, Inc.), 
and SMC1 (1:8,000; Novus Biologicals). Human ATM complexes were 
purified from 293T cells by sequential anti-Flag and anti-HA immunopre-
cipitation, and kinase assays were performed as previously described (Lee 
and Paull, 2005). In brief, kinase assays were performed in kinase buffer 
composed of 50 mM Hepes, pH 7.5, 50 mM KCl, 5 mM MgCl2, 10% 
glycerol, 1 mM ATP, and 1 mM DTT for 90 min at 30°C.
Online supplemental material
Fig. S1 shows that integration of the Atm D2899A mutant transgene in 
each founder occurs on a different chromosome than endogenous Atm 
using metaphase FISH. Fig. S2 shows that ATM kinase activity is dispens-
able for ATM recruitment to DNA breaks using laser microirradiation and 
immunofluorescence microscopy. Fig. S3 shows FACS histograms of YFP 
expression in bone marrow and spleen subsets and Southern blot analysis 
of digested genomic DNA assaying for rearrangement of the pMX-INV– 
integrated substrate within v-Abl–transformed pre-B cell lines, indicative of 
RAG-dependent DNA recombination. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.201204035/DC1.
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